Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.39 |
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | NAMPT | P43490 | 2/20 | 0.39 |
| ▸ | GRM5 | P41594 | 7/20 | 0.38 |
| ▸ | VNN1 | O95497 | 4/20 | 0.37 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6178079 | 0.84 | GSK3B (0.41) | ELANEGSK3BNAMPTGRM5 | |
| SCHEMBL6248270 | 0.80 | VNN1 (0.41) | ELANENAMPTGRM5VNN1ADORA2A | |
| SCHEMBL6246189 | 0.74 | CA1 (0.46) | — | |
| SCHEMBL5697248 | 0.73 | GRM5 (0.39) | GSK3BNAMPTGRM5VNN1 | |
| SCHEMBL6181453 | 0.71 | GPR183 (0.41) | GSK3BNAMPTSLC6A7 | |
| SCHEMBL27924000 | 0.66 | NAMPT (0.63) | GSK3BNAMPTGRM5 | |
| SCHEMBL2320890 | 0.65 | GRM5 (0.57) | NAMPTGRM5SLC6A7 | |
| SCHEMBL2760493 | 0.65 | NAMPT (0.53) | GSK3BNAMPTGRM5SLC6A7 | |
| SCHEMBL3634940 | 0.65 | HPGD (0.60) | NAMPTADORA2A | |
| SCHEMBL2740504 | 0.64 | SIGMAR1 (0.61) | GSK3BNAMPTGRM5SLC6A7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6977261-B2 | Azaisoquinoline derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2005-12-20 | — | — | US | disclosed |
| EP-1539709-A1 | AZAISOQUINOLINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040038961-A1 | Azaisoquinoline derivatives as matrix metalloproteinase inhibitors | BUNKER AMY MAE (US) | 2004-02-26 | — | — | US | disclosed |
| WO-2004014866-A1 | AZAISOQUINOLINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038961-A1 | Azaisoquinoline derivatives as matrix metalloproteinase inhibitors | MMP13, MMP9, MMP1 | ELANE 1223/4885GSK3B 241/4885NAMPT 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.